Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Study: Japan Reaches Biosimilar Patient Access Faster Than USA, EU

Study: Japan Reaches Biosimilar Patient Access Faster Than USA, EU

November 22, 2026 Business Desk Business

Patient access to biosimilars in Japan reaches commercial markets faster than in the United States or the European Union despite persistent regulatory approval lags, according to a study published on November 21, 2026 in Naunyn-Schmiedeberg’s Archives of Pharmacology.

The research, titled “From regulatory approval to patient access: A comparative analysis of biosimilar market entry timelines in Japan, the USA, and the EU,” was authored by Miya Kawasaki, Yuka Saino, Anri Nishizawa, Aya Hariu, and Ryosuke Kuribayashi, according to PubMed.

Authors Miya Kawasaki, Yuka Saino, Anri Nishizawa, and Ryosuke Kuribayashi are affiliated with the Office of Cellular and Tissue-Based Products at the Pharmaceuticals and Medical Devices Agency in Tokyo, Japan, while Ryosuke Kuribayashi is also associated with the agency’s Office of Regulatory Science Research.

The study highlights that biosimilar approval lag and biosimilar loss—also referred to as the biosimilar void—remain important challenges particularly in Japan compared with the USA and the EU.

Investigators evaluated biosimilar approval lag, market entry lag, and patient access time, which was defined as the interval between regulatory approval and first commercial launch. The initial commercial release functioned as the primary quantifiable indicator for patient access, rather than serving as an assessment of how frequently biosimilars were subsequently utilized in clinical settings.

Analyses were conducted using publicly available data from Japan’s Pharmaceuticals and Medical Devices Agency, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), supplemented by company press releases.

The findings revealed that the median patient access time was shortest in Japan at 6 months, compared with 15 months in the USA and 17 months in the EU. Even with a continuous delay in approvals, the availability of biosimilars for patients in Japan was often on par with, or ahead of, availability in the USA and the EU, primarily due to the reduced time between approval and market introduction.

The Pharmaceuticals and Medical Devices Agency functions as an Independent Administrative Institution tasked with ensuring the safety, efficacy, and quality of medical products in Japan. Beyond its regulatory review role, the agency manages a unique victim compensation program that provides financial support for medical costs and lost wages to individuals who experience injury or disability resulting from the use of medical products, as well as to those infected with HIV through blood transfusions.

To modernize its operations, the organization shifted its submission process in 2017 by adopting the International Council for Harmonisation Electronic Common Technical Document format for all electronic regulatory filings.

The authors concluded that regulatory approval timing alone is insufficient to assess patient access to biosimilars. To guarantee that patients can access treatments in a timely manner, it is necessary to implement a holistic strategy that combines post-approval procedures—such as reimbursement, pricing, and market entry—alongside synchronized initiatives throughout the entire lifespan of a biosimilar.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related reading

  • French Court Rules Co-Owners Must Pay for Common Equipment Charges Despite Personal Disconnection Choice
  • Twenty-one fourth-grade students in Monte di Malo have refused to eat school meals for a week
  • Russian Drone Strikes Hit Ukraine; Kryvyi Rih Wounded Reaches 73 (newsy-today.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service